Saturday, June 24, 2017

ERAP1 at the 2017 EULAR Annual Meeting in Madrid

I’ve written about ERAP1 at the EULAR 2014 Meeting in Paris, where I had gotten interested in two abstracts and guessed [1]: “My guess is that it isn’t the last we hear about ERAP1 in ankylosing spondylitis.” Let’s have a look at ERAP1 at the 2017 EULAR Annual Meeting in Madrid.

A. de Koning and colleagues presented [2]: “ERAP1 IS A SUSCEPTIBILITY FACTOR FOR EARLY AXIAL SPONDYLOARTHRITIS MEETING THE ASAS CLASSIFICATION CRITERIA: RESULTS FROM THE DESIR AND SPACE COHORTS”. Conclusions: “ERAP1 rs30187 is a genetic risk factor for early axSpA. To our knowledge this is the first report of genetic risk factor research in early axSpA [axial spondyloarthritis] patients meeting the ASAS [Assessment of SpondyloArthritis] criteria [3]. Larger cohorts are needed to study additional AS [ankylosing spondylitis] risk factors.”

J. Londono and colleagues looked at [4]: “THU0005 ERAP POLYMORPHISMS AND ITS ASSOCIATION WITH HLA-B15 AND HLA-B27 POSITIVE SPONDYLARTHRITIS PATIENTS”. “Since 1973, the association of HLA-B27 and spondyloarthritis (SpA) is well known, however in Colombian population it is present in only 40% of patients and HLA-B15 is present almost in 25%.” Conclusions:” In the group of patients analysed, a statistically significant association was found between patients with SpA HLA-B15 positive and the haplotype TGT of ERAP2. Also HLA-B27 positive SpA patients were associated with haplotype TGC and CAT of ERAP2 with statistical significance”. Interestingly there were no associations between ERAP1 haplotypes and HLA-B15 or B27 in this Colombian cohort.

ERAP1 and also ERAP2 haplotypes open new horizons for research in ankylosing spondylitis and maybe we’ll use these genetic factors later in a probability index to calculate the risk for forms of spondyloarthritis.

Links and References:
[2] DOI: 10.1136/annrheumdis-2017-eular.5955
[4] DOI: 10.1136/annrheumdis-2017-eular.5659


No comments:

Post a Comment